Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized long-term study of Oxabact in primary hyperoxaluria
2017-000684-33Phase 3Completed
- Sponsor
- OxThera AB
- Start
- Apr 2017
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxalobacter formigenes in Primary hyperoxaluria (PH) and Not applicable (2 arms), sponsored by OxThera AB. Primary endpoint: Change from baseline in total plasma oxalate concentration after 52 weeks of treatment. Started Apr 2017; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)Not applicable
Beyond the preview
Go deeper on 2017-000684-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000684-33.